Symphogen's proprietary pipeline includes three mAb mixture product candidates: Sym004, Sym013 and Sym015. Each of these products has the potential to offer a clinical treatment option for cancer patients that is not currently available. 

Our proprietary pipeline is based on clinically validated targets, is supported by strong preclinical data, and has broad intellectual property protection. It is designed to address today's need for precision medicine.

Our pipeline also includes partnered programs: a clinical-stage program directed to an undisclosed infectious disease target that is under clinical development by Genentech, and an immuno-oncology discovery/preclinical program addressing up to six immuno-oncology targets being developed in collaboration with Shire.

In addition to the clinical pipeline, we maintain comprehensive discovery and preclinical activities to continue to realize the potential of our mAb mixture platform, including in immuno-oncology.